Innaxon, s.r.o. is an early stage development company based at InnoCrystal, Czech Republic.
Innaxon's in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin® and Novo-Pyrexal®) and in-licensed small molecule inhibitors (IAXOTM compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively.
![SCHOOL BAGPACK low poly gray SCHOOL BAGPACK low poly gray](https://www.innaxon.cz/wp-content/uploads/2018/04/Innaxon-3-2.jpg)
![Innaxon sro_3 Innaxon sro_3](https://www.innaxon.cz/wp-content/uploads/2021/02/Innaxon-sro_3.jpg)
Innaxon continuously seeks further partnerships with academic, pharmaceutical and clinical research centres to harness innate immunity for therapeutic benefit in the field of
- vaccine adjuvants
- immuno(chemo)therapy
- anti-inflammatory agents